Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 1/20 | 0.53 |
| ▸ | CMA1 | P23946 | 1/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | GLS | O94925 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12750998 | 0.88 | CTSG (0.51) | CTSGCMA1SLC7A5ALDH1A1GAA | |
| SCHEMBL2768397 | 0.86 | CTSG (0.52) | CTSGCMA1SLC7A5ALDH1A1GAA | |
| SCHEMBL4873552 | 0.84 | SIRT2 (0.48) | ALDH1A1GAAHSD17B10GLSSMN1; SMN2 | |
| SCHEMBL9026247 | 0.84 | PTGS1 (0.45) | ALDH1A1GAAHSD17B10GLSSMN1; SMN2 | |
| SCHEMBL12400239 | 0.82 | SLC7A5 (0.68) | CTSGCMA1SLC7A5ALDH1A1GAA | |
| SCHEMBL2767340 | 0.82 | CTSG (0.49) | CTSGCMA1SLC7A5ALDH1A1GAA | |
| SCHEMBL12984975 | 0.81 | ALDH1A1 (0.50) | ALDH1A1GAAHSD17B10GLSSMN1; SMN2 | |
| SCHEMBL335277 | 0.81 | ALDH1A1 (0.54) | ALDH1A1GAAHSD17B10GLSSMN1; SMN2 | |
| SCHEMBL48506 | 0.81 | ALDH1A1 (0.50) | ALDH1A1GAAHSD17B10GLSSMN1; SMN2 | |
| SCHEMBL5051584 | 0.81 | CTSG (0.48) | CTSGCMA1SLC7A5ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149718-A1 | Amido Compounds | BROTHERTON-PLEISS CHRISTINE E (US) | 2012-06-14 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| EP-1558607-B1 | COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2010-05-05 | — | — | EP | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7514448-B2 | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1756108-A2 | AZAINDOLES USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2007-02-28 | — | — | EP | disclosed |
| US-7157476-B2 | Aminofurazan compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1660467-A2 | AMINOFURAZAN COMPOUNDS AS PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20060003968-A1 | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2006-01-05 | — | — | US | disclosed |
| WO-2005103050-A2 | AZAINDOLES USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-11-03 | — | — | WO | disclosed |
| EP-1558607-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20050148640-A1 | Aminofurazan compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2005-07-07 | — | — | US | disclosed |
| WO-2005019190-A2 | (4 -AMINO -1,2, 5-OXADIAZOL-4-YL) -HETΞROAROMATIC COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040122016-A1 | Compositions useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-24 | — | — | US | disclosed |
| WO-2004041813-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148640-A1 | Aminofurazan compounds useful as protein kinase inhibitors | PHKG1, MAP3K20, MAP3K5 | CTSG 3200/4885CMA1 1248/4885SLC7A5 1647/4885 |
| US-20040122016-A1 | Compositions useful as inhibitors of rock and other protein kinases | ROCK1, ROCK2, PRKCH | CTSG 1694/4885CMA1 1109/4885SLC7A5 4471/4885 |
| US-20060003968-A1 | Azaindoles useful as inhibitors of rock and other protein kinases | ROCK2, ROCK1, TNK2 | CTSG 3186/4885CMA1 1388/4885SLC7A5 4028/4885 |
| US-20120149718-A1 | Amido Compounds | P2RX7, P2RX3, P2RX2 | CTSG 1932/4885CMA1 3192/4885SLC7A5 1243/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | CTSG 1018/4885CMA1 613/4885SLC7A5 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.